If you or a loved one is taking Tysabri and experiencing new neurological symptoms, understanding the typical timeline of PML onset is critical. Decades of pharmacovigilance have established a clear pattern of symptom progression that clinicians rely on for early detection. This page outlines how PML symptoms are documented in medical records and what the chronology of clinical signals looks like.
Tysabri (natalizumab) is a biologic therapy approved for the treatment of multiple sclerosis and Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe and often fatal brain infection caused by the JC virus (JCV). The U.S. Food and Drug Administration (FDA) has assigned a boxed warning to Tysabri, the agency's most stringent safety alert, specifically addressing this risk. The warning states that "TYSABRI increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This warning is repeated in the prescribing information, emphasizing that PML is a known adverse effect of the drug. PML is a demyelinating disease of the central nervous system caused by the JC polyomavirus. It primarily affects individuals with compromised immune systems, such as those receiving immunosuppressive therapies. A large retrospective cohort study of Italian PML patients observed between 1987 and 2024 included 456 cases, with 82.4% having a definite diagnosis and 17.6% a clinico-radiological diagnosis (https://pubmed.ncbi.nlm.nih.gov/40922664/). This study underscores the severity and diagnostic challenges of PML, which can present with a range of neurological symptoms.
The mechanistic link between Tysabri and PML involves the drug's mode of action. Tysabri is a monoclonal antibody that binds to alpha-4 integrins on the surface of immune cells, preventing their migration from the bloodstream into the central nervous system. This action reduces inflammation in conditions like multiple sclerosis but also impairs immune surveillance against JCV. The FDA's boxed warning identifies three key risk factors for PML in Tysabri-treated patients: "the presence of anti-JCV antibodies, duration of therapy, and prior use of immunosuppressants" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients who are anti-JCV antibody positive have a higher risk, and the risk increases with longer treatment duration, especially beyond two years. Prior use of immunosuppressants further elevates this risk. The prescribing information advises healthcare professionals to "monitor patients on TYSABRI for any new sign or symptom that may be suggestive of PML" and to "withhold TYSABRI immediately at the first sign or symptom suggestive of PML" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Symptoms of PML can include progressive weakness on one side of the body, clumsiness, visual disturbances, and changes in thinking, memory, and personality. Because PML can progress rapidly, early detection and discontinuation of Tysabri are critical.
The FDA Adverse Event Reporting System (FAERS) database lists adverse events most frequently associated with Tysabri, including fatigue (19,150 reports), multiple sclerosis relapse (16,691 reports), headache (9,626 reports), and gait disturbance (9,422 reports) (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). While these reports do not directly quantify PML incidence, they reflect the range of neurological and systemic effects reported by patients. PML itself is a rare but devastating event, and its occurrence has led to the implementation of a restricted distribution program called the TOUCH Prescribing Program, which aims to ensure that patients are monitored for PML symptoms. For patients who develop PML after Tysabri treatment, the timeline between exposure and documented harm can vary. PML may occur months to years after starting therapy, with risk increasing with cumulative exposure. The FDA's boxed warning notes that "longer treatment duration, especially beyond 2 years" is a risk factor (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This latency period can complicate the attribution of harm, as patients may not immediately associate neurological symptoms with their medication.
Adequacy of warnings regarding Tysabri and PML is a critical issue. The FDA has mandated a boxed warning and a restricted distribution program, which are among the strongest regulatory measures available. However, questions may arise about whether patients and healthcare providers fully understand the magnitude of the risk, particularly in the context of individual risk factors like JCV antibody status. The prescribing information states that "these factors should be considered in the context of expected benefit when initiating and continuing treatment with TYSABRI" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these warnings, some patients may still experience PML, leading to severe disability or death. Attorney-related considerations for affected patients are important. Patients who develop PML after Tysabri treatment may seek legal counsel to explore whether the drug's manufacturer provided adequate warnings or if there were failures in monitoring or risk communication. The boxed warning and TOUCH program represent efforts to mitigate risk, but legal claims may focus on whether these measures were sufficient in individual cases. Patients should be aware that the timeline between exposure and harm, as well as the presence of known risk factors, can influence legal arguments. In summary, Tysabri is associated with a known risk of PML, a severe brain infection that can lead to death or disability. The FDA has issued a boxed warning and established a restricted distribution program to manage this risk. Patients and healthcare providers must remain vigilant for PML symptoms, especially in those with anti-JCV antibodies, longer treatment duration, or prior immunosuppressant use. For those affected, legal avenues may be available to address potential inadequacies in warnings or monitoring.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Tysabri (natalizumab) is a biologic therapy for multiple sclerosis and Crohn's disease. It increases the risk of progressive multifocal leukoencephalopathy (PML), a severe brain infection caused by the JC virus. The FDA has issued a boxed warning about this risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
The three key risk factors are: presence of anti-JCV antibodies, longer treatment duration (especially beyond 2 years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
Symptoms include progressive weakness on one side of the body, clumsiness, visual disturbances, and changes in thinking, memory, or personality. Immediate medical attention is needed if these occur (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
Yes, affected patients may consult an attorney to evaluate whether the drug manufacturer provided adequate warnings or if there were failures in monitoring. Legal claims may focus on the sufficiency of risk communication and the TOUCH program.
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.